Eli lilly and company LLY.US 總覽分析
)LLY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，不過公司股利評分優異，若想穩定收息，仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作
LLY 近期報酬表現
-11.66%
Eli lilly and company
1.86%
同產業平均
0.63%
S&P500
與 LLY 同產業的標的表現
- NVO Novo nordisk as價值 2 分趨勢 2 分波段 4 分籌碼 2 分股利 5 分查看更多
LLY 公司資訊
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.